RBC Capital lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $415 from $423 and keeps a Sector Perform rating on the shares. Compared to Q2, the company registered a more uneventful quarter, the analyst tells investors in a research note. Vertex’s cystic fibrosis, CF, franchise remains healthy, though slow launches elsewhere and increased spend underscore intrinsic limitations to operating leverage growth as the company diversifies, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Optimistic Outlook for Vertex Pharmaceuticals Driven by Strong CF Business and Promising Pipeline Developments
- Vertex Pharmaceuticals price target lowered to $445 from $455 at Stifel
- Vertex Pharmaceuticals: Strong Buy Rating Amid Promising Growth and Strategic Expansion
- Vertex Pharmaceuticals: Hold Rating Maintained Amid Mixed Financial Signals
- Vertex Pharmaceuticals price target raised to $414 from $408 at Barclays